Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Islatravir - Merck Sharp & Dohme

X
Drug Profile

Islatravir - Merck Sharp & Dohme

Alternative Names: 4-ethynyl-2-fluoro-2-deoxyadenosine; EFdA; MK-8519; MK-8591; MK-8591-eluting implant; MK-8591D

Latest Information Update: 28 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Gilead Sciences; Merck Sharp & Dohme
  • Class Alkynes; Antiretrovirals; Fluorinated hydrocarbons; Purine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV-1 infections
  • No development reported HIV infections
  • Discontinued HIV-2 infections

Most Recent Events

  • 28 Apr 2024 No recent reports of development identified for phase-I development in HIV-infections in Unknown (SC, Implant)
  • 03 Mar 2024 Efficacy and adverse events data from a phase II trial in HIV-1 infections released by Gilead Sciences at the 31st Conference on Retroviruses and Opportunistic Infections 2024 (CROI-2024)
  • 27 Apr 2023 Merck Sharp & Dohme reinitiates enrolment in a phase III MK-8591A-019 trial in HIV-1 infections (In adolescents, In adults, In children, In the elderly, Treatment-experienced) in France, UK, Portugal, Denmark, the US, Germany, South Korea, Russia, Ukraine, Spain, South Africa, Peru, Japan, Italy, Colombia, Chile, Canada and Australia, as US FDA places full clinical hold on the trials (NCT04233216) (EudraCT2019-000588-26)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top